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AbstrAct 
Purpose: To examine the prevalence of ocular surface complaints in Brazilian 
patients with glaucoma or ocular hypertension who used topical intraocular 
pres sure (IOP)-lowering regimens. 
Methods: In this multicenter, noninterventional, single-visit study, adults with 
glaucoma or ocular hypertension treated with an IOP-lowering regimen were 
administered the 12-item ocular surface disease index (OSDI) questionnaire. Each 
response was scored on a 5-point scale, with 0 indicating symptom present none 
of the time and 4 indicating symptom present all of the time. The average of the 
12 item responses for each patient was transformed to a scale from 0 to 100, with 
higher scores representing worse disabilities. OSDI results then were categorized 
as absence of OSD (scores of 0-12), mild OSD (scores of 13-22), moderate OSD 
(scores of 23-32), or severe OSD (scores of 33100). 
results: The 173 enrolled patients had a mean age of 61.2 years, were women in 
65.3% of cases, and had glaucoma in 89.0% of cases and ocular hypertension in 
11.0% of cases. OSDI scores for 158 patients using 1 IOP-lowering therapy indicated 
no OSD in 37.3% of patients (59/158), mild OSD in 20.9% (33/158), moderate OSD 
in 17.1% (27/158), and severe OSD in 24.7% (39/158). For the 120 patients using 1 
IOP-lowering medication and having a known duration of diagnosis of glaucoma 
or ocular hypertension, mean OSDI scores were numerically higher (worse) for 
the 39 patients with a diagnosis ≥6 years long (score 25 [± 20], indicating mo-
derate OSD) than for the 81 patients with a diagnosis lasting <6 years (score 22 
[± 20], indicating mild OSD); however, no significant differences in OSDI scores 
by duration of diagnosis were evident in means (P=0.49), distributions (P≥0.26), 
or correlation (P=0.77). 
conclusions: A large proportion of Brazilian patients treated with 1 IOP-lowering 
therapy had some ocular surface complaints.
Keywords: Glaucoma; Ocular hypertension/therapy; Dry eye syndromes/drug the -
rapy; Preservatives, pharmaceutical/therapeutic use; Brazil
RESUMO
Objetivo: Avaliar a prevalência de sintomas decorrentes de doença de superfície ocular 
(DSO) em pacientes brasileiros com glaucoma ou hipertensão ocular que utilizam 
tratamento ocular tópico para redução da pressão intraocular (PIO). 
Método: Neste estudo multicêntrico, não intervencional de uma única visita, pacientes 
adultos com glaucoma ou hipertensão ocular em tratamento para redução da pres-
são intraocular (PIO) responderam aos 12 itens do questionário “índice de doença da 
superfície ocular” (OSDI). Cada resposta foi pontuada numa escala de 5 pontos, com 
0 (zero) indicando a ausência de sintomas e 4 indicando sintomas presentes todo o 
tempo. A média de respostas dos 12 itens para cada paciente foi transformada numa 
escala de 0 a 100, com pontuações mais elevadas representando piores deficiências. 
Os resultados do OSDI foram categorizados como ausência de DSO (pontuação de 
0-12), DSO leve (pontuação de 13-22), DSO moderada (pontuação de 23-32) ou DSO 
grave (pontuação de 33-100). 
Resultados: Os 173 pacientes incluídos apresentavam idade média de 61,2 anos, 
65,3% eram mulheres (65,3%), tinham glaucoma em 89,0% dos casos e hipertensão 
ocular em 11,0% dos casos. As pontuações do OSDI para os 158 pacientes utilizando 
uma medicação para redução da PIO indicaram “DSO ausente” em 37,3% dos pacientes 
(59/158), “DSO leve” em 20,9% (33/158), “DSO moderada” em 17,1% (27/158) e “DSO 
grave” em 24,7% (39/158). Para os 120 pacientes utilizando medicação redutora da 
PIO e com duração conhecida do diagnóstico de glaucoma ou hipertensão ocular, 
a pontuação média do OSDI foi numericamente superior (pior) para 39 pacientes 
com diagnóstico realizado há mais de 6 anos (pontuação 25 [± 20] indicando DSO 
moderado) do que para 81 pacientes com o diagnóstico realizado há menos de 6 
anos (pontuação 22 [± 20] indicando DSO leve); no entanto, não houve diferença 
estatisticamente significativa na média da pontuação OSDI na duração do diagnóstico 
(P=0.49), distribuição (P≥0,26), ou correlação (P=0,77). 
Conclusão: Uma grande proporção de pacientes brasileiros tratados com uma me -
dicação para redução da PIO apresenta sintomas decorrentes de doença da superfície 
ocular (DSO).
Descritores: Glaucoma; Hipertensão ocular/quimioterapia; Síndrome do olho seco/
quimioterapia; Conservantes farmacêuticos/uso terapêutico
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IntroductIon
Ocular surface disease (OSD) is a multifactorial ocular condition 
associated with inadequate tear film volume, tear film instability, and 
damage to the ocular surface(1). Clinically meaningful signs such as 
rapid tear film breakup, high tear osmolarity, and increased ocular 
surface staining also may be observed in patients with OSD(2). Indi-
viduals with OSD may experience the symptoms of ocular dryness, 
burning/stinging, itching, irritation, tearing, foreign body sensation, 
redness, and blurred vision, at varying levels of severity(2). Because of 
the overlap of the signs and symptoms of OSD versus dry eye disease, 
the literature to date has often treated these diseases interchangea-
bly. Studies suggest that OSD or dry eye disease can negatively affect 
overall quality of life(3), functional visual acuity(4), and the ability to 
carry out daily tasks (eg, driving and participating in sports and other 
leisure activities, such as reading and cooking)(4). 
Approximately 15% of the general elderly population in the Uni -
ted States experiences some level of symptomatic OSD(5). Studies in 
the United States(6), Australia(7), and Brazil(8) have indicated that the 
prevalence of OSD or dry eye is higher in glaucoma patients than in 
the nonglaucomatous population. The etiology of OSD in patients 
with glaucoma is thought to be multifactorial. Anterior segment 
ocular disorders such as allergy, blepharitis, dry eye, or eyelid anato-
mical abnormalities may contribute to the onset or exacerbation of 
OSD(2). The use of preservative-containing topical ocular medications 
to lower intraocular pressure (IOP) may be another key factor. Topical 
ocular IOP-lowering drugs that contain the preservative benzalko-
nium chloride (BAK) may trigger or exacerbate OSD by inducing 
ocular surface damage(9). The effects of BAK on the ocular surface may 
increase over time due to chronic exposure, since IOP-lowering me -
dications are generally administered daily for many years, and since 
multiple medications are sometimes required to achieve and main-
tain desired IOP-lowering effects(9). 
A recent global study noted that patients who were enrolled 
at clinics in Latin America (Argentina, Colombia, and Mexico), had 
OSD that was significantly worse than the OSD of Asian patients or 
Cau casian patients globally(10). Since race and geography may be 
important to OSD prevalence, this study was designed to determine 
the prevalence of ocular surface complaints in a Brazilian population 
of patients with glaucoma or ocular hypertension who were on an 
IOP-lowering regimen.
Methods
This multicenter, noninterventional, single-visit study at four 
study centers in Brazil evaluated the ocular surface complaints of pa-
tients with glaucoma or ocular hypertension. Upon entry, all patients 
pro vided their written informed consent. An independent Ethics 
Committee approved the protocol and the qualifications of all of the 
participating investigators. The study was conducted in accordance 
with Good Clinical Practices and the ethical principles described 
within the Declaration of Helsinki.
During a regularly scheduled clinic visit, eligible patients completed 
the Ocular Surface Disease Index (OSDI) questionnaire. Demographic 
information, medical histories, and use of concomitant medications, 
including artificial tears, were recorded. Eligible patients were men 
and women of any race or ethnicity, at least 18 years of age, who had a 
best-corrected visual acuity of at least 20/60 Snellen in each eye, who 
were diagnosed with ocular hypertension or glaucoma (closed-angle, 
open-angle, pseudoexfoliation, or pigment dispersion), and who were 
receiving any topical ocular regimen to lower IOP. 
The OSDI is a 12 item, disease specific quality-of-life question-
naire used to quantify the effect of dry eye on vision-related quality 
of life. The OSDI questionnaire has been validated for its test-retest 
reliability and its usefulness to clinically differentiate among absence 
of OSD, mild to moderate OSD, and severe OSD(11). The questionnaire 
includes three subscales: ocular discomfort (OSDI symptoms), func-
tioning (OSDI- function), and environmental triggers (OSDI-triggers). 
The individual items within the subscales refer to a 1-week recall 
period; possible responses to each item are based on the frequency 
of the associated disturbance. Each response was scored based on 
a scale that ranged from 0 (none of the time) to 4 (all of the time). 
The average score for each of the 12 items rated by each patient 
was transformed to a scale ranging from 0 to 100, with higher scores 
representing worse disability. Ocular surface disease index results 
then were categorized as absence of OSD (scores of 0-12), mild OSD 
(scores of 13-22), moderate OSD (scores of 23-32), or severe OSD 
(scores of 33100), as previously described(11,12). 
Descriptive statistics (including number, percentage, mean, 
stan dard deviation, and range) were calculated for demographics, 
baseline characteristics, and OSDI scores. Mean OSDI scores also were 
summarized by the categorical time since diagnosis of glaucoma or 
ocular hypertension (ie, 1 category for patients with a diagnosis shor-
ter than the mean number of years since diagnosis and 1 category for 
patients with a diagnosis longer than or equal to the mean number 
of years since diagnosis); the comparison of the mean values of those 
2 subgroups was performed using a 2-sample t-test, with inferences 
drawn at an alpha level of 0.05. Comparisons between groups of the 
distribution of patients with normal OSDI scores vs. all other patients 
and of the distribution of patients with severe OSD scores vs. all other 
patients were performed using a Chi-square test. The interaction 
between OSDI scores and duration of current glaucoma therapy was 
analyzed using a Pearson correlation. Statistics were analyzed using 
Statistica version 5.1/97. 
results
A total of 173 patients were enrolled at 4 investigational centers 
in Brazil (Table 1). The 173 patients were 13 to 88 years of age, with 
a mean (± standard deviation, SD) age of 61.2 (± 14.3) years. The 
majority of patients (68.8%) were Caucasian and 65.3% were women. 
Most patients (89.0%) had a diagnosis of glaucoma (primary open-
an gle glaucoma, 74.0%; closed-angle glaucoma, 13.3%; open-angle 
glaucoma with pseudoexfoliation, 1.7%) and the remainder (11.0%) 
had ocular hypertension. Fourteen patients were excluded from 
the analysis for protocol deviations (8 patients who were using an 
“unknown” number of IOP-lowering medications, and 6 patients who 
were using more than 1 medication), leaving 159 patients eligible for 
analysis. 
One patient did not answer all of the OSDI questions, yielding 
evaluable OSDI data for 158 patients. Of those, 37.3% (59 of 158) had 
OSDI scores indicating absence of OSD. The remainder of the popu-
lation - approximately two thirds of the patients (62.7%, 99 of 158; 
95% confidence interval 55.2% to 70.2%) - had OSDI scores indicating 
some degree of OSD. Scores indicated mild OSD in 33 of 158 patients 
(20.9%), moderate OSD in 27 of 158 patients (17.1%), and severe OSD 
in 39 of 172 patients (24.7%); (Figure 1).
In the overall population of 173 patients, 40 had an unknown 
duration of diagnosis of glaucoma or ocular hypertension. Of those 
with a known duration (n=133), the mean (± SD) time since diagnosis 
of glaucoma or ocular hypertension was 6.0 (± 6.9) years. That mean 
value was used as the basis for dividing patients into categories of 
duration since glaucoma diagnosis (ie, < 6 years and ≥ 6 years). After 
excluding for protocol deviations related to number of IOP-lowering 
medications and for incomplete responses to the OSDI question-
naire, 120 patients were evaluable for duration of diagnosis versus 
OSDI score. Mean OSDI scores were higher (worse) for patients in the 
longer-duration diagnosis category than for those in the shorter-du-
ration diagnosis category. Specifically, evaluable patients who had a 
diagnosis of <6 years (n=81) had a mean (± SD) OSDI score of 22 
(± 20) units, indicating mild severity OSD, while patients with a 
diagnosis of 6 years or longer (n=39) had a mean (± SD) OSDI score 
of 25 (± 20) units, indicating moderate severity OSD. However, diffe-
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rences in OSDI scores in terms of duration of diagnosis were not sta-
tistically significant by t-test of means (P=0.49) or when investigated 
by Pearson correlation (P=0.77). The poorer mean OSDI score in the 
longer-duration group (with respect to the shorter-duration group) 
appeared to be due to a smaller proportion of patients without OSD 
and a larger proportion of patients with severe OSD, as shown in 
figure 2A. These proportions were not significantly different by Chi-
squa re tests between shorter-duration and longer-duration groups 
(P=0.43 for severe OSD and P=0.26 for absence of OSD) as shown in 
figure 2B. 
dIscussIon
In individuals with glaucoma or ocular hypertension, ocular sur-
face complaints are common. Scores on OSDI questionnaires in this 
study indicated that 62.7% of patients who had glaucoma or ocular 
hypertension and who were using 1 IOP-lowering medication had 
mild, moderate, or severe OSD. That overall prevalence of OSD was 
slightly higher than the reported prevalence of dry eye among glau-
coma patients in Germany (53%)(13) or the OSDI-based prevalence of 
OSD among glaucoma patients in the United States (48%-59%)(1,14) or 
globally (59.2%)(10). When compared to other OSDI-based studies, the 
prevalence of severe OSD in patients with glaucoma or ocular hyper-
tension observed in this study (24.7%) was slightly higher than its 
prevalence in one previous study in the United States (13.8%)(14), was 
approximately similar to its prevalence in a global study (20.3%)(10), 
and was slightly lower than its prevalence (27%) reported in another 
study in the United States(1). However, results from the current study 
of patients using 1 IOP-lowering medication cannot easily be compa-
red with other studies of patients using 1 or more IOP-lowering medi-
cations, since many of those studies have reported that relationships 
may exist between higher numbers of IOP-lowering medications and 
worse signs or symptoms of OSD or dry eye disease(1,11,13,14). 
The high prevalence of mild, moderate, or severe OSD as classi-
fied in this study may be multifactorial, with factors including an terior 
segment ocular disorders such as allergy, blepharitis, dry eye, or eyelid 
anatomical abnormalities(2). Moreover, environmental issues in Brazil 
may influence ocular surface integrity(15). In addition, results may be 
partially attributed to frequent use of BAK-preserved medications(9). 
Due to its broad spectrum of antimicrobial efficacy and its effects on 
the tight junctions between corneal epithelial cells (which facilitates 
ocular penetration of active compounds), BAK is the most widely 
used preservative in ophthalmic preparations(9,16). When compared 
with preservative-free medication, long-term topical ocular use of 
BAK-preserved medications in patients with glaucoma has been 
associated with ocular surface alterations. One such alteration is a 
decrease in goblet cell density associated with BAK-preserved thera-
py that was significantly larger than the decrease with unpreserved 
therapy(17). Another such alteration is lower tear production volume 
and greater tear film instability in patients using BAK-preserved the-
rapies versus those using unpreserved therapy(18). These BAK-induced 
effects may be reversible or partially reversible in some cases; swi-
tching patients with mild OSD from a BAK-preserved IOP-lowering 
therapy to an alternatively preserved IOP-lowering therapy resulted 
in a mean OSDI score that indicated absence of clinically significant 
OSD and that was significantly better than the mean OSDI score for 
patients who continued on a BAK-preserved IOP-lowering therapy(19). 
Alternatives to BAK-preserved therapies include preservative-free 
therapies and alternatively preserved therapies. Various advantages 
of preservative-free therapies for ocular health have been demonstra-
ted(17,18,20). Alternative preservatives (eg, Purite® from Allergan; SofZia® 
buffer system and Polyquad® preservative from Alcon) are intended 
to be gentler to the ocular surface than BAK(21) and have been used 
in reformulating BAK-preserved IOP-lowering medications, which 
may offer patients with glaucoma or ocular hypertension alternate 
therapies and may reduce their exposure to BAK. Preservative-free 





Mean (standard deviation) 061.2 (14.3)









Diagnosis type, n (%)
Ocular hypertension 019 (11.0)
Primary open-angle glaucoma 128 (74.0)
Open-angle glaucoma with pseudoexfoliation 003 (01.7)
Open-angle glaucoma with pigment dispersion 000 (00.0)
Closed-angle glaucoma 023 (13.3)
Time since diagnosis, years
Mean (standard deviation) 006 (06.9)
< 6 years, n (%) 086 (49.7)
≥ 6 years, n (%) 047 (27.2)
Unknown duration, n (%) 040 (23.1)
Number of glaucoma medications
Mean (standard deviation) 001.0 (00.2)
1, n (%)b 159 (91.9)
2 or 3, n (%) 006 (03.5)
Unknown, n (%) 008 (04.6)
a= one patient younger than 18 years of age was enrolled and included in the study 
endpoint analyses. b=  Included monotherapies and fixed-combination therapies.
OSD = ocular surface disease.
Figure 1. Ocular surface disease index (OSDI) score category results for patients with 
glaucoma or ocular hypertension at four study centers in Brazil. 
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or alternatively preserved therapies may be important to potentially 
help preserve the ocular surface health of patients who use ophthal-
mic product(s) over many years. 
Some studies have reported associations between worse OSD 
or dry eye and longer-term use of IOP-lowering medications (in 
terms of a surrogate for that variable - longer duration of diagnosis). 
These associations have been observed as trends over time(13) and 
as significant differences between duration categories(10). In the 
current study, patients who had glaucoma or ocular hypertension 
for <6 years had mean OSDI scores of 22 ± 20, indicative of mild 
OSD, while patients with longer histories of glaucoma or ocular 
hypertension had worse mean OSDI scores (25 ± 20), indicating 
moderate OSD; however, the difference in scores was not statisti-
cally significant. 
Some study limitations were related to the multitude of variables. 
This was evident in the wide variation (ie, large SDs) in the mean 
OSDI scores for the population, which made data interpretation 
complicated. The pathogenesis of OSD in patients with glaucoma is 
multifactorial. While the role of preserved topical ocular drops in OSD 
has been well-studied, other anterior segment ocular conditions (eg, 
blepharitis, allergies, or anatomic abnormalities of the eyelid[s]) are 
known to exacerbate OSD(2). Collecting data about comorbid con-
ditions and determining the impact of all these factors on the OSD 
prevalence was beyond the scope of this study.
An additional study limitation was the nature of the OSDI trans -
lation. While a recent translation to Portuguese of the OSDI has been 
reported to have good inter-observer and intra-observer agree-
Figure 2. A) Proportions of ocular surface disease (OSD) Index categories, sorted by duration of diagnosis. B) P-values show chi-square results for severe OSD versus any other OSD 
category (left panel) or no OSD versus any other OSD category (right panel).
A
b
ment(22), that version was not available to us at the time of our study. 
Supplementing the subjective OSDI with objective assessments of 
the ocular surface would have made it possible to determine the 
pre valence of OSD rather than simply presenting the prevalence 
of its symptoms. However, the purpose of the study was solely to 
examine the prevalence of ocular surface complaints in Brazilian 
patients on IOP-lowering therapy, and this aim was accomplished. 
Although it would have been interesting to determine the preva-
lence of OSD, the correlation between the signs and symptoms of 
OSD has been poor(23). 
Despite study limitations, findings for these patients in Brazil were 
generally in agreement with studies in other countries that observed 
a high prevalence of ocular surface complaints among patients with 
glaucoma or ocular hypertension. A recent report examining factors 
related to glaucoma treatment compliance among Brazilian patients 
revealed that side effects of eye drops were the most frequently ci-
ted reason for noncompliance(24). This suggests that patients scoring 
high on the OSDI, half of whose 12 items deal directly with ocular 
discomfort, may be at risk for noncompliance. 
conclusIon 
Thus, Brazilian clinicians should be aware of the high prevalence 
of abnormal OSDI scores among patients with glaucoma or ocular 
hypertension and should address any ocular surface complaints in 
these patients so that they can maintain compliance with their IOP-
lo wering medications.
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